How the Newest Dupilumab Approval Solves an "Unmet Need" in Children with AD

Earlier this month, dupilumab became the first and only biologic medicine approved by the US Food and Drug Administration for the treatment of atopic dermatitis in patients of all ages, from infancy through adulthood. The approval of dupilumab as an add-on maintenance therapy for children 6 months to 5 years with moderate to severe atopic dermatitis was described as “a tremendous advancement” by Mercades E. Gonzalez, MD, FAAD, pediatric dermatologist at Pediatric Dermatology of Miami. Gonzalez joined the DocTalk program to speak on the unmet need for therapies such as dupilumab for young children affected by AD, and the various psychological and mental burdens of the skin disease.